Vanino E.; Tadolini M.; Attard L.; Cascavilla A.; Pea F.; Viale P., A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care, «INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE», 2019, 23, pp. 1042 - 1043 [replica/breve intervento]
Giacobbe D.R.; De Rosa F.G.; Del Bono V.; Grossi P.A.; Pea F.; Petrosillo N.; Rossolini G.M.; Tascini C.; Tumbarello M.; Viale P.; Bassetti M., Ceftobiprole: drug evaluation and place in therapy, «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2019, 17, pp. 689 - 698 [articolo]Open Access
Pea F.; Krause R.; Muller C.; Hennart B.; Richardson M.; Meinitzer A.; Wiesen M.H.J.; Wiktorowicz T.; Spickermann J.; Henriksen A.S., Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays among European Laboratories, «THERAPEUTIC DRUG MONITORING», 2019, 41, pp. 657 - 664 [articolo]
Cojutti, Pier Giorgio; Maximova, Natalia; Schillani, Giulia; Hope, William; Pea, Federico, Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2019, 74, pp. 1648 - 1655 [articolo]
Cojutti P.G.; Merelli M.; Bassetti M.; Pea F., Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: Findings from a monocentric, prospective, open-label, interventional study, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2019, 74, pp. 3588 - 3595 [articolo]
Crass R.L.; Cojutti P.G.; Pai M.P.; Pea F., Reappraisal of linezolid dosing in renal impairment to improve safety, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2019, 63, pp. 1 - 9 [articolo]
Cojutti P.G.; Merelli M.; Allegri L.; Damante G.; Bassetti M.; Pea F., Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2019, 85, pp. 266 - 269 [articolo]
Righi, Elda; Carnelutti, Alessia; Baccarani, Umberto; Sartor, Assunta; Cojutti, Piergiorgio; Bassetti, Matteo; Pea, Federico, Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful?, «TRANSPLANT INFECTIOUS DISEASE», 2019, 21, pp. e13113 - - [articolo]
Pascale R.; Giannella M.; Bartoletti M.; Viale P.; Pea F., Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections, «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2019, 17, pp. 819 - 827 [articolo]
Posteraro B.; Pea F.; Masucci L.; Posteraro P.; Sanguinetti M., Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2018, 18, pp. 469 - 476 [articolo]
Righi E.; Muser D.; Carnelutti A.; Pea F.; Sartor A.; Bassetti M., Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report, «DRUGS & THERAPY PERSPECTIVES», 2018, 34, pp. 402 - 403 [articolo]
Peghin M.; Maiani M.; Castaldo N.; Givone F.; Righi E.; Lechiancole A.; Sartor A.; Pea F.; Livi U.; Bassetti M., Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant, «INFECTION», 2018, 46, pp. 263 - 265 [replica/breve intervento]
Cojutti P.G.; Candoni A.; Lazzarotto D.; Rabassi N.; Fanin R.; Hope W.; Pea F., Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 84, pp. 2544 - 2550 [articolo]
Cojutti P.G.; Merelli M.; De Stefanis P.; Fregonese C.; Lucchese F.; Bassetti M.; Pea F., Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 74, pp. 1671 - 1672 [replica/breve intervento]
Cojutti P.G.; Barbarino C.; De Monte A.; Hope W.; Pea F., Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 74, pp. 1091 - 1092 [articolo]
